STOCK TITAN
  1. Home
  2. Sec-filings
  3. REGN
  4. [144] REGENERON PHARMACEUTICALS, INC. SEC Filing

Regeneron director plans $340K stock sale

REGENERON PHARMACEUTICALS, INC.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

REGENERON PHARMACEUTICALS, INC. (REGN) is named as the issuer in a Form 144 notice covering a proposed sale of its common stock by director Kathryn Guarini. The notice reports a planned sale of 400 shares of common stock on or after September 2, 2026, with an aggregate market value of $340,000, to be effected through UBS Financial Services Inc.

The shares are indicated as being issuable upon the exercise of a stock option on September 2, 2026, for cash. The filing also reports that Guarini sold 400 shares of Regeneron common stock on August 10, 2026, with an aggregate market value of $320,000, during the prior three months.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 400 shares Common stock covered by the Form 144 notice for September 2, 2026
Aggregate market value of proposed sale $340,000 Value listed for 400 Regeneron common shares in the Form 144 securities information
Date of proposed transaction September 2, 2026 Date tied to the 400-share sale and option exercise
Shares sold in prior 3 months 400 shares Regeneron common shares sold by Kathryn Guarini on August 10, 2026
Aggregate market value of prior sale $320,000 Value reported for the August 10, 2026 sale of 400 shares
Signature date February 13, 2026 Date accompanying the Form 144 signature by UBS Financial Services Inc. as attorney-in-fact
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Exercise of stock option financial
"Common | 09/02/2026 | Exercise of stock option | Issuer"
attorney-in-fact regulatory
"Signature | /s/ UBS Financial Services Inc., as attorney-in-fact for Kathryn"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing disclose for REGENERON PHARMACEUTICALS, INC. (REGN)?
It discloses that director Kathryn Guarini has filed a notice of proposed sale under Rule 144 for 400 shares of Regeneron common stock, with an aggregate market value of $340,000, expected on or after September 2, 2026.

How many REGN shares is Kathryn Guarini planning to sell under this Form 144?
The notice covers a proposed sale of 400 shares of Regeneron common stock. The filing lists an aggregate market value of approximately $340,000 for this block, to be transacted through UBS Financial Services Inc. on or after September 2, 2026.

How were the REGN shares in the new Form 144 to be obtained?
The 400 shares covered by the notice are stated as issuable upon the exercise of a stock option on September 2, 2026, for cash. The exercise is identified as the source of the securities to be sold by the director’s account.

What prior REGN stock sales by Kathryn Guarini are reported in the last three months?
The filing reports that Kathryn Guarini sold 400 shares of Regeneron common stock on August 10, 2026, with an aggregate market value of $320,000, as securities sold during the past three months.

Who is executing the proposed REGN share sale disclosed in the Form 144?
The proposed sale of 400 shares of Regeneron common stock is to be executed through UBS Financial Services Inc. at its New York office, as indicated in the securities information section of the Form 144 notice.

What exchange is referenced for the REGN shares in this Form 144?
The Form 144 lists the issuer’s common stock as traded on Nasdaq. The notice pertains specifically to Regeneron’s common shares planned for sale under Rule 144 by director Kathryn Guarini.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR